Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ONCO
stocks logo

ONCO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
--
--
-714.000
+31.25%
Estimates Revision
Stock Price
Go Up
up Image
+6.12%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Onconetix Inc (ONCO.O) is -0.00, compared to its 5-year average forward P/E of -2.41. For a more detailed relative valuation and DCF analysis to assess Onconetix Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.41
Current PE
-0.00
Overvalued PE
6.04
Undervalued PE
-10.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
7.13
Undervalued EV/EBITDA
-12.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.65
Current PS
0.00
Overvalued PS
51.27
Undervalued PS
-29.97
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ONCO News & Events

Events Timeline

(ET)
2025-09-26
08:35:52
Onconetix Secures Funding via Private Placement and Debt Resolution
select
2025-09-26
08:18:00
Onconetix and Ocuvex mutually agree to terminate merger deal
select
2025-09-22 (ET)
2025-09-22
08:08:10
Onconetix Grants Manufacturing IP License to Immunovia for Proteomedix
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
09-26Newsfilter
Onconetix Secures $12.9 Million in Financing via Series D Preferred Stock and Warrants, Ends Merger Agreement with Ocuvex, Inc., and Settles $8.8 Million Debt with Veru, Inc.

  • Financing Transaction Details: Onconetix, Inc. completed a private placement on September 22, 2025, raising approximately $12.9 million through the sale of Series D Convertible Preferred Stock and warrants, with a portion of the proceeds used to pay off debt to Veru, Inc.

  • Use of Proceeds: The company plans to utilize the remaining funds for costs related to terminating a previous business combination with Ocuvex, Inc., as well as for working capital and general corporate purposes.

[object Object]
Preview
8.5
09-26Newsfilter
Joint Announcement: Onconetix and Ocuvex Declare End of Merger Agreement

  • Merger Termination: Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths for the benefit of their stakeholders.

  • Future Plans: Ocuvex has received its New Jersey state pharmaceutical license and is set to launch its product Omlonti soon, while Onconetix remains focused on its men's health and oncology solutions.

[object Object]
Preview
9.5
07-31Benzinga
Why Meta Platforms Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

  • Meta Platforms Financial Results: Meta Platforms, Inc. reported second-quarter revenue of $47.52 billion and earnings of $7.14 per share, both exceeding analyst expectations, leading to an 11.7% increase in pre-market trading.

  • Stock Movements: Various stocks experienced significant pre-market movements, with VerifyMe, Inc. rising 57.4% after a partnership announcement, while Align Technology, Inc. fell 34.2% due to missed earnings estimates.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Onconetix Inc (ONCO) stock price today?

The current price of ONCO is 2.95 USD — it has decreased -1.34 % in the last trading day.

arrow icon

What is Onconetix Inc (ONCO)'s business?

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

arrow icon

What is the price predicton of ONCO Stock?

Wall Street analysts forecast ONCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Onconetix Inc (ONCO)'s revenue for the last quarter?

Onconetix Inc revenue for the last quarter amounts to 303.65K USD, decreased -25.37 % YoY.

arrow icon

What is Onconetix Inc (ONCO)'s earnings per share (EPS) for the last quarter?

Onconetix Inc. EPS for the last quarter amounts to -6.25 USD, decreased -97.49 % YoY.

arrow icon

What changes have occurred in the market's expectations for Onconetix Inc (ONCO)'s fundamentals?

The market is revising No Change the revenue expectations for ONCO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 6.12%.
arrow icon

How many employees does Onconetix Inc (ONCO). have?

Onconetix Inc (ONCO) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Onconetix Inc (ONCO) market cap?

Today ONCO has the market capitalization of 4.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free